nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—HTR2A—myenteric nerve plexus—systemic scleroderma	0.0185	0.167	CbGeAlD
Atomoxetine—HTR2A—pulmonary artery—systemic scleroderma	0.0131	0.118	CbGeAlD
Atomoxetine—HTR1B—artery—systemic scleroderma	0.0101	0.091	CbGeAlD
Atomoxetine—HTR1D—artery—systemic scleroderma	0.00978	0.0881	CbGeAlD
Atomoxetine—HTR1B—blood vessel—systemic scleroderma	0.00787	0.0709	CbGeAlD
Atomoxetine—HTR1D—blood vessel—systemic scleroderma	0.00762	0.0687	CbGeAlD
Atomoxetine—NPY1R—lung—systemic scleroderma	0.00574	0.0517	CbGeAlD
Atomoxetine—HTR2A—artery—systemic scleroderma	0.00486	0.0438	CbGeAlD
Atomoxetine—HTR2A—endothelium—systemic scleroderma	0.0041	0.037	CbGeAlD
Atomoxetine—HTR1D—connective tissue—systemic scleroderma	0.00391	0.0352	CbGeAlD
Atomoxetine—HTR2A—blood vessel—systemic scleroderma	0.00378	0.0341	CbGeAlD
Atomoxetine—SLC6A4—digestive system—systemic scleroderma	0.00265	0.0239	CbGeAlD
Atomoxetine—SLC6A3—lung—systemic scleroderma	0.00241	0.0218	CbGeAlD
Atomoxetine—SLC6A4—lung—systemic scleroderma	0.00221	0.0199	CbGeAlD
Atomoxetine—CYP2C19—digestive system—systemic scleroderma	0.00219	0.0198	CbGeAlD
Atomoxetine—SLC6A2—lung—systemic scleroderma	0.00195	0.0175	CbGeAlD
Atomoxetine—HTR2A—connective tissue—systemic scleroderma	0.00194	0.0175	CbGeAlD
Atomoxetine—HTR2A—smooth muscle tissue—systemic scleroderma	0.00177	0.016	CbGeAlD
Atomoxetine—HTR2A—digestive system—systemic scleroderma	0.0014	0.0126	CbGeAlD
Atomoxetine—HTR2A—tendon—systemic scleroderma	0.00133	0.012	CbGeAlD
Atomoxetine—CYP3A4—digestive system—systemic scleroderma	0.0013	0.0117	CbGeAlD
Atomoxetine—CYP2D6—digestive system—systemic scleroderma	0.00128	0.0115	CbGeAlD
Atomoxetine—HTR2A—lung—systemic scleroderma	0.00117	0.0105	CbGeAlD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000956	0.00107	CcSEcCtD
Atomoxetine—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.000952	0.00107	CcSEcCtD
Atomoxetine—Lethargy—Methotrexate—systemic scleroderma	0.000951	0.00107	CcSEcCtD
Atomoxetine—Dyspepsia—Leflunomide—systemic scleroderma	0.000945	0.00106	CcSEcCtD
Atomoxetine—Vomiting—Mometasone—systemic scleroderma	0.000943	0.00106	CcSEcCtD
Atomoxetine—Dry mouth—Lisinopril—systemic scleroderma	0.000941	0.00106	CcSEcCtD
Atomoxetine—Sweating increased—Prednisone—systemic scleroderma	0.000939	0.00106	CcSEcCtD
Atomoxetine—Feeling abnormal—Azathioprine—systemic scleroderma	0.000937	0.00105	CcSEcCtD
Atomoxetine—Rash—Mometasone—systemic scleroderma	0.000935	0.00105	CcSEcCtD
Atomoxetine—Asthenia—Captopril—systemic scleroderma	0.000935	0.00105	CcSEcCtD
Atomoxetine—Dermatitis—Mometasone—systemic scleroderma	0.000934	0.00105	CcSEcCtD
Atomoxetine—Decreased appetite—Leflunomide—systemic scleroderma	0.000933	0.00105	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000933	0.00105	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.00093	0.00105	CcSEcCtD
Atomoxetine—Headache—Mometasone—systemic scleroderma	0.000929	0.00105	CcSEcCtD
Atomoxetine—Tremor—Mycophenolate mofetil—systemic scleroderma	0.000928	0.00104	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000927	0.00104	CcSEcCtD
Atomoxetine—Insomnia—Mycophenolic acid—systemic scleroderma	0.000926	0.00104	CcSEcCtD
Atomoxetine—Fatigue—Leflunomide—systemic scleroderma	0.000926	0.00104	CcSEcCtD
Atomoxetine—Pruritus—Captopril—systemic scleroderma	0.000922	0.00104	CcSEcCtD
Atomoxetine—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.00092	0.00103	CcSEcCtD
Atomoxetine—Pain—Leflunomide—systemic scleroderma	0.000918	0.00103	CcSEcCtD
Atomoxetine—Constipation—Leflunomide—systemic scleroderma	0.000918	0.00103	CcSEcCtD
Atomoxetine—Infection—Lisinopril—systemic scleroderma	0.000916	0.00103	CcSEcCtD
Atomoxetine—Somnolence—Mycophenolic acid—systemic scleroderma	0.000911	0.00102	CcSEcCtD
Atomoxetine—Agitation—Mycophenolate mofetil—systemic scleroderma	0.00091	0.00102	CcSEcCtD
Atomoxetine—Shock—Lisinopril—systemic scleroderma	0.000908	0.00102	CcSEcCtD
Atomoxetine—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000902	0.00101	CcSEcCtD
Atomoxetine—Tachycardia—Lisinopril—systemic scleroderma	0.0009	0.00101	CcSEcCtD
Atomoxetine—Abdominal pain—Azathioprine—systemic scleroderma	0.000899	0.00101	CcSEcCtD
Atomoxetine—Body temperature increased—Azathioprine—systemic scleroderma	0.000899	0.00101	CcSEcCtD
Atomoxetine—Skin disorder—Lisinopril—systemic scleroderma	0.000896	0.00101	CcSEcCtD
Atomoxetine—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000892	0.001	CcSEcCtD
Atomoxetine—Diarrhoea—Captopril—systemic scleroderma	0.000891	0.001	CcSEcCtD
Atomoxetine—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.00089	0.001	CcSEcCtD
Atomoxetine—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.00089	0.001	CcSEcCtD
Atomoxetine—Irritability—Methotrexate—systemic scleroderma	0.000889	0.001	CcSEcCtD
Atomoxetine—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000888	0.000999	CcSEcCtD
Atomoxetine—Erectile dysfunction—Prednisone—systemic scleroderma	0.000887	0.000998	CcSEcCtD
Atomoxetine—Feeling abnormal—Leflunomide—systemic scleroderma	0.000885	0.000995	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000884	0.000995	CcSEcCtD
Atomoxetine—Fatigue—Mycophenolic acid—systemic scleroderma	0.000883	0.000993	CcSEcCtD
Atomoxetine—Mood swings—Methotrexate—systemic scleroderma	0.000883	0.000993	CcSEcCtD
Atomoxetine—Nausea—Mometasone—systemic scleroderma	0.000881	0.000991	CcSEcCtD
Atomoxetine—Anorexia—Lisinopril—systemic scleroderma	0.000879	0.000989	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000878	0.000987	CcSEcCtD
Atomoxetine—Pain—Mycophenolic acid—systemic scleroderma	0.000876	0.000985	CcSEcCtD
Atomoxetine—Constipation—Mycophenolic acid—systemic scleroderma	0.000876	0.000985	CcSEcCtD
Atomoxetine—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000875	0.000984	CcSEcCtD
Atomoxetine—Weight decreased—Prednisone—systemic scleroderma	0.000872	0.00098	CcSEcCtD
Atomoxetine—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.00087	0.000979	CcSEcCtD
Atomoxetine—Cough—Mycophenolate mofetil—systemic scleroderma	0.000864	0.000972	CcSEcCtD
Atomoxetine—Dizziness—Captopril—systemic scleroderma	0.000861	0.000969	CcSEcCtD
Atomoxetine—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000858	0.000965	CcSEcCtD
Atomoxetine—Depression—Prednisone—systemic scleroderma	0.000857	0.000963	CcSEcCtD
Atomoxetine—Urticaria—Leflunomide—systemic scleroderma	0.000853	0.000959	CcSEcCtD
Atomoxetine—Abdominal pain—Leflunomide—systemic scleroderma	0.000849	0.000955	CcSEcCtD
Atomoxetine—Body temperature increased—Leflunomide—systemic scleroderma	0.000849	0.000955	CcSEcCtD
Atomoxetine—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000844	0.000949	CcSEcCtD
Atomoxetine—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000843	0.000948	CcSEcCtD
Atomoxetine—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000843	0.000948	CcSEcCtD
Atomoxetine—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000843	0.000948	CcSEcCtD
Atomoxetine—Breast disorder—Methotrexate—systemic scleroderma	0.000842	0.000947	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.00084	0.000945	CcSEcCtD
Atomoxetine—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.00084	0.000945	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000838	0.000942	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000837	0.000942	CcSEcCtD
Atomoxetine—Insomnia—Lisinopril—systemic scleroderma	0.000834	0.000938	CcSEcCtD
Atomoxetine—Paraesthesia—Lisinopril—systemic scleroderma	0.000828	0.000932	CcSEcCtD
Atomoxetine—Vomiting—Captopril—systemic scleroderma	0.000828	0.000932	CcSEcCtD
Atomoxetine—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000825	0.000928	CcSEcCtD
Atomoxetine—Rash—Captopril—systemic scleroderma	0.000821	0.000924	CcSEcCtD
Atomoxetine—Dermatitis—Captopril—systemic scleroderma	0.000821	0.000923	CcSEcCtD
Atomoxetine—Somnolence—Lisinopril—systemic scleroderma	0.00082	0.000922	CcSEcCtD
Atomoxetine—Headache—Captopril—systemic scleroderma	0.000816	0.000918	CcSEcCtD
Atomoxetine—Dyspepsia—Lisinopril—systemic scleroderma	0.000812	0.000913	CcSEcCtD
Atomoxetine—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.00081	0.000911	CcSEcCtD
Atomoxetine—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.00081	0.000911	CcSEcCtD
Atomoxetine—Infection—Mycophenolate mofetil—systemic scleroderma	0.000803	0.000903	CcSEcCtD
Atomoxetine—Decreased appetite—Lisinopril—systemic scleroderma	0.000802	0.000902	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000796	0.000896	CcSEcCtD
Atomoxetine—Fatigue—Lisinopril—systemic scleroderma	0.000795	0.000895	CcSEcCtD
Atomoxetine—Shock—Mycophenolate mofetil—systemic scleroderma	0.000795	0.000894	CcSEcCtD
Atomoxetine—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000793	0.000892	CcSEcCtD
Atomoxetine—Pain—Lisinopril—systemic scleroderma	0.000789	0.000887	CcSEcCtD
Atomoxetine—Constipation—Lisinopril—systemic scleroderma	0.000789	0.000887	CcSEcCtD
Atomoxetine—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000789	0.000887	CcSEcCtD
Atomoxetine—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000785	0.000883	CcSEcCtD
Atomoxetine—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000781	0.000879	CcSEcCtD
Atomoxetine—Diarrhoea—Azathioprine—systemic scleroderma	0.000778	0.000875	CcSEcCtD
Atomoxetine—Nausea—Captopril—systemic scleroderma	0.000774	0.00087	CcSEcCtD
Atomoxetine—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000772	0.000868	CcSEcCtD
Atomoxetine—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.00077	0.000867	CcSEcCtD
Atomoxetine—Asthenia—Leflunomide—systemic scleroderma	0.00077	0.000866	CcSEcCtD
Atomoxetine—Hallucination—Prednisone—systemic scleroderma	0.000767	0.000863	CcSEcCtD
Atomoxetine—Feeling abnormal—Lisinopril—systemic scleroderma	0.00076	0.000855	CcSEcCtD
Atomoxetine—Pruritus—Leflunomide—systemic scleroderma	0.00076	0.000854	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000754	0.000848	CcSEcCtD
Atomoxetine—Dysuria—Methotrexate—systemic scleroderma	0.000753	0.000847	CcSEcCtD
Atomoxetine—Dizziness—Azathioprine—systemic scleroderma	0.000752	0.000846	CcSEcCtD
Atomoxetine—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000748	0.000842	CcSEcCtD
Atomoxetine—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000742	0.000834	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000736	0.000828	CcSEcCtD
Atomoxetine—Asthenia—Mycophenolic acid—systemic scleroderma	0.000735	0.000827	CcSEcCtD
Atomoxetine—Diarrhoea—Leflunomide—systemic scleroderma	0.000735	0.000826	CcSEcCtD
Atomoxetine—Urticaria—Lisinopril—systemic scleroderma	0.000733	0.000824	CcSEcCtD
Atomoxetine—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000731	0.000822	CcSEcCtD
Atomoxetine—Abdominal pain—Lisinopril—systemic scleroderma	0.000729	0.00082	CcSEcCtD
Atomoxetine—Body temperature increased—Lisinopril—systemic scleroderma	0.000729	0.00082	CcSEcCtD
Atomoxetine—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000726	0.000816	CcSEcCtD
Atomoxetine—Pruritus—Mycophenolic acid—systemic scleroderma	0.000725	0.000815	CcSEcCtD
Atomoxetine—Vomiting—Azathioprine—systemic scleroderma	0.000723	0.000813	CcSEcCtD
Atomoxetine—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000719	0.000808	CcSEcCtD
Atomoxetine—Infestation—Methotrexate—systemic scleroderma	0.000718	0.000808	CcSEcCtD
Atomoxetine—Infestation NOS—Methotrexate—systemic scleroderma	0.000718	0.000808	CcSEcCtD
Atomoxetine—Rash—Azathioprine—systemic scleroderma	0.000717	0.000806	CcSEcCtD
Atomoxetine—Dermatitis—Azathioprine—systemic scleroderma	0.000716	0.000806	CcSEcCtD
Atomoxetine—Depression—Methotrexate—systemic scleroderma	0.000716	0.000805	CcSEcCtD
Atomoxetine—Flushing—Prednisone—systemic scleroderma	0.000716	0.000805	CcSEcCtD
Atomoxetine—Headache—Azathioprine—systemic scleroderma	0.000712	0.000801	CcSEcCtD
Atomoxetine—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000712	0.0008	CcSEcCtD
Atomoxetine—Dizziness—Leflunomide—systemic scleroderma	0.00071	0.000799	CcSEcCtD
Atomoxetine—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000703	0.00079	CcSEcCtD
Atomoxetine—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000701	0.000788	CcSEcCtD
Atomoxetine—Angiopathy—Prednisone—systemic scleroderma	0.0007	0.000787	CcSEcCtD
Atomoxetine—Conjunctivitis—Methotrexate—systemic scleroderma	0.000698	0.000785	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000698	0.000785	CcSEcCtD
Atomoxetine—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000691	0.000777	CcSEcCtD
Atomoxetine—Pain—Mycophenolate mofetil—systemic scleroderma	0.000691	0.000777	CcSEcCtD
Atomoxetine—Vomiting—Leflunomide—systemic scleroderma	0.000683	0.000768	CcSEcCtD
Atomoxetine—Dizziness—Mycophenolic acid—systemic scleroderma	0.000677	0.000762	CcSEcCtD
Atomoxetine—Rash—Leflunomide—systemic scleroderma	0.000677	0.000761	CcSEcCtD
Atomoxetine—Dermatitis—Leflunomide—systemic scleroderma	0.000676	0.000761	CcSEcCtD
Atomoxetine—Mental disorder—Prednisone—systemic scleroderma	0.000676	0.00076	CcSEcCtD
Atomoxetine—Nausea—Azathioprine—systemic scleroderma	0.000675	0.00076	CcSEcCtD
Atomoxetine—Headache—Leflunomide—systemic scleroderma	0.000673	0.000757	CcSEcCtD
Atomoxetine—Malnutrition—Prednisone—systemic scleroderma	0.000671	0.000755	CcSEcCtD
Atomoxetine—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000666	0.000749	CcSEcCtD
Atomoxetine—Asthenia—Lisinopril—systemic scleroderma	0.000662	0.000744	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000661	0.000743	CcSEcCtD
Atomoxetine—Pruritus—Lisinopril—systemic scleroderma	0.000653	0.000734	CcSEcCtD
Atomoxetine—Vomiting—Mycophenolic acid—systemic scleroderma	0.000651	0.000732	CcSEcCtD
Atomoxetine—Rash—Mycophenolic acid—systemic scleroderma	0.000646	0.000726	CcSEcCtD
Atomoxetine—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000645	0.000726	CcSEcCtD
Atomoxetine—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000642	0.000722	CcSEcCtD
Atomoxetine—Headache—Mycophenolic acid—systemic scleroderma	0.000642	0.000722	CcSEcCtD
Atomoxetine—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000639	0.000719	CcSEcCtD
Atomoxetine—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000639	0.000719	CcSEcCtD
Atomoxetine—Nausea—Leflunomide—systemic scleroderma	0.000638	0.000717	CcSEcCtD
Atomoxetine—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000636	0.000716	CcSEcCtD
Atomoxetine—Vision blurred—Prednisone—systemic scleroderma	0.000633	0.000712	CcSEcCtD
Atomoxetine—Urethral disorder—Methotrexate—systemic scleroderma	0.000632	0.000711	CcSEcCtD
Atomoxetine—Diarrhoea—Lisinopril—systemic scleroderma	0.000631	0.00071	CcSEcCtD
Atomoxetine—Agitation—Prednisone—systemic scleroderma	0.000617	0.000694	CcSEcCtD
Atomoxetine—Dizziness—Lisinopril—systemic scleroderma	0.00061	0.000686	CcSEcCtD
Atomoxetine—Nausea—Mycophenolic acid—systemic scleroderma	0.000608	0.000684	CcSEcCtD
Atomoxetine—Vertigo—Prednisone—systemic scleroderma	0.000603	0.000678	CcSEcCtD
Atomoxetine—Syncope—Prednisone—systemic scleroderma	0.000602	0.000677	CcSEcCtD
Atomoxetine—Cardiac disorder—Methotrexate—systemic scleroderma	0.000598	0.000673	CcSEcCtD
Atomoxetine—Loss of consciousness—Prednisone—systemic scleroderma	0.00059	0.000664	CcSEcCtD
Atomoxetine—Vomiting—Lisinopril—systemic scleroderma	0.000587	0.00066	CcSEcCtD
Atomoxetine—Angiopathy—Methotrexate—systemic scleroderma	0.000585	0.000658	CcSEcCtD
Atomoxetine—Rash—Lisinopril—systemic scleroderma	0.000582	0.000654	CcSEcCtD
Atomoxetine—Convulsion—Prednisone—systemic scleroderma	0.000582	0.000654	CcSEcCtD
Atomoxetine—Dermatitis—Lisinopril—systemic scleroderma	0.000581	0.000654	CcSEcCtD
Atomoxetine—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000581	0.000653	CcSEcCtD
Atomoxetine—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.00058	0.000652	CcSEcCtD
Atomoxetine—Chills—Methotrexate—systemic scleroderma	0.000578	0.00065	CcSEcCtD
Atomoxetine—Headache—Lisinopril—systemic scleroderma	0.000578	0.00065	CcSEcCtD
Atomoxetine—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000572	0.000643	CcSEcCtD
Atomoxetine—Arthralgia—Prednisone—systemic scleroderma	0.000572	0.000643	CcSEcCtD
Atomoxetine—Myalgia—Prednisone—systemic scleroderma	0.000572	0.000643	CcSEcCtD
Atomoxetine—Anxiety—Prednisone—systemic scleroderma	0.00057	0.000641	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000568	0.000638	CcSEcCtD
Atomoxetine—Mental disorder—Methotrexate—systemic scleroderma	0.000565	0.000635	CcSEcCtD
Atomoxetine—Malnutrition—Methotrexate—systemic scleroderma	0.000561	0.000631	CcSEcCtD
Atomoxetine—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000553	0.000622	CcSEcCtD
Atomoxetine—Dysgeusia—Methotrexate—systemic scleroderma	0.000549	0.000618	CcSEcCtD
Atomoxetine—Nausea—Lisinopril—systemic scleroderma	0.000548	0.000616	CcSEcCtD
Atomoxetine—Infection—Prednisone—systemic scleroderma	0.000544	0.000612	CcSEcCtD
Atomoxetine—Back pain—Methotrexate—systemic scleroderma	0.000543	0.00061	CcSEcCtD
Atomoxetine—Shock—Prednisone—systemic scleroderma	0.000539	0.000606	CcSEcCtD
Atomoxetine—Nervous system disorder—Prednisone—systemic scleroderma	0.000537	0.000604	CcSEcCtD
Atomoxetine—Tachycardia—Prednisone—systemic scleroderma	0.000535	0.000601	CcSEcCtD
Atomoxetine—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000535	0.000601	CcSEcCtD
Atomoxetine—Skin disorder—Prednisone—systemic scleroderma	0.000532	0.000599	CcSEcCtD
Atomoxetine—Hyperhidrosis—Prednisone—systemic scleroderma	0.00053	0.000596	CcSEcCtD
Atomoxetine—Vision blurred—Methotrexate—systemic scleroderma	0.000529	0.000595	CcSEcCtD
Atomoxetine—Anorexia—Prednisone—systemic scleroderma	0.000522	0.000587	CcSEcCtD
Atomoxetine—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000514	0.000578	CcSEcCtD
Atomoxetine—Rash—Mycophenolate mofetil—systemic scleroderma	0.00051	0.000573	CcSEcCtD
Atomoxetine—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000509	0.000573	CcSEcCtD
Atomoxetine—Headache—Mycophenolate mofetil—systemic scleroderma	0.000506	0.00057	CcSEcCtD
Atomoxetine—Vertigo—Methotrexate—systemic scleroderma	0.000504	0.000567	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000499	0.000561	CcSEcCtD
Atomoxetine—Insomnia—Prednisone—systemic scleroderma	0.000496	0.000557	CcSEcCtD
Atomoxetine—Paraesthesia—Prednisone—systemic scleroderma	0.000492	0.000553	CcSEcCtD
Atomoxetine—Cough—Methotrexate—systemic scleroderma	0.00049	0.000551	CcSEcCtD
Atomoxetine—Convulsion—Methotrexate—systemic scleroderma	0.000486	0.000547	CcSEcCtD
Atomoxetine—Dyspepsia—Prednisone—systemic scleroderma	0.000482	0.000542	CcSEcCtD
Atomoxetine—Nausea—Mycophenolate mofetil—systemic scleroderma	0.00048	0.00054	CcSEcCtD
Atomoxetine—Chest pain—Methotrexate—systemic scleroderma	0.000478	0.000537	CcSEcCtD
Atomoxetine—Arthralgia—Methotrexate—systemic scleroderma	0.000478	0.000537	CcSEcCtD
Atomoxetine—Myalgia—Methotrexate—systemic scleroderma	0.000478	0.000537	CcSEcCtD
Atomoxetine—Decreased appetite—Prednisone—systemic scleroderma	0.000476	0.000536	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000474	0.000534	CcSEcCtD
Atomoxetine—Fatigue—Prednisone—systemic scleroderma	0.000472	0.000531	CcSEcCtD
Atomoxetine—Constipation—Prednisone—systemic scleroderma	0.000469	0.000527	CcSEcCtD
Atomoxetine—Infection—Methotrexate—systemic scleroderma	0.000455	0.000512	CcSEcCtD
Atomoxetine—Feeling abnormal—Prednisone—systemic scleroderma	0.000451	0.000508	CcSEcCtD
Atomoxetine—Nervous system disorder—Methotrexate—systemic scleroderma	0.000449	0.000505	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000448	0.000504	CcSEcCtD
Atomoxetine—Skin disorder—Methotrexate—systemic scleroderma	0.000445	0.0005	CcSEcCtD
Atomoxetine—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000443	0.000498	CcSEcCtD
Atomoxetine—Anorexia—Methotrexate—systemic scleroderma	0.000436	0.000491	CcSEcCtD
Atomoxetine—Urticaria—Prednisone—systemic scleroderma	0.000435	0.00049	CcSEcCtD
Atomoxetine—Body temperature increased—Prednisone—systemic scleroderma	0.000433	0.000487	CcSEcCtD
Atomoxetine—Abdominal pain—Prednisone—systemic scleroderma	0.000433	0.000487	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000417	0.000469	CcSEcCtD
Atomoxetine—Insomnia—Methotrexate—systemic scleroderma	0.000414	0.000466	CcSEcCtD
Atomoxetine—Paraesthesia—Methotrexate—systemic scleroderma	0.000411	0.000462	CcSEcCtD
Atomoxetine—Somnolence—Methotrexate—systemic scleroderma	0.000407	0.000458	CcSEcCtD
Atomoxetine—Dyspepsia—Methotrexate—systemic scleroderma	0.000403	0.000453	CcSEcCtD
Atomoxetine—Decreased appetite—Methotrexate—systemic scleroderma	0.000398	0.000448	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000395	0.000445	CcSEcCtD
Atomoxetine—Fatigue—Methotrexate—systemic scleroderma	0.000395	0.000444	CcSEcCtD
Atomoxetine—Asthenia—Prednisone—systemic scleroderma	0.000393	0.000442	CcSEcCtD
Atomoxetine—Pain—Methotrexate—systemic scleroderma	0.000392	0.00044	CcSEcCtD
Atomoxetine—Pruritus—Prednisone—systemic scleroderma	0.000388	0.000436	CcSEcCtD
Atomoxetine—Feeling abnormal—Methotrexate—systemic scleroderma	0.000377	0.000424	CcSEcCtD
Atomoxetine—Diarrhoea—Prednisone—systemic scleroderma	0.000375	0.000422	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000374	0.000421	CcSEcCtD
Atomoxetine—Urticaria—Methotrexate—systemic scleroderma	0.000364	0.000409	CcSEcCtD
Atomoxetine—Dizziness—Prednisone—systemic scleroderma	0.000362	0.000408	CcSEcCtD
Atomoxetine—Abdominal pain—Methotrexate—systemic scleroderma	0.000362	0.000407	CcSEcCtD
Atomoxetine—Body temperature increased—Methotrexate—systemic scleroderma	0.000362	0.000407	CcSEcCtD
Atomoxetine—Vomiting—Prednisone—systemic scleroderma	0.000348	0.000392	CcSEcCtD
Atomoxetine—Rash—Prednisone—systemic scleroderma	0.000345	0.000389	CcSEcCtD
Atomoxetine—Dermatitis—Prednisone—systemic scleroderma	0.000345	0.000388	CcSEcCtD
Atomoxetine—Headache—Prednisone—systemic scleroderma	0.000343	0.000386	CcSEcCtD
Atomoxetine—Asthenia—Methotrexate—systemic scleroderma	0.000329	0.00037	CcSEcCtD
Atomoxetine—Nausea—Prednisone—systemic scleroderma	0.000325	0.000366	CcSEcCtD
Atomoxetine—Pruritus—Methotrexate—systemic scleroderma	0.000324	0.000364	CcSEcCtD
Atomoxetine—Diarrhoea—Methotrexate—systemic scleroderma	0.000313	0.000352	CcSEcCtD
Atomoxetine—Dizziness—Methotrexate—systemic scleroderma	0.000303	0.000341	CcSEcCtD
Atomoxetine—Vomiting—Methotrexate—systemic scleroderma	0.000291	0.000327	CcSEcCtD
Atomoxetine—Rash—Methotrexate—systemic scleroderma	0.000289	0.000325	CcSEcCtD
Atomoxetine—Dermatitis—Methotrexate—systemic scleroderma	0.000288	0.000324	CcSEcCtD
Atomoxetine—Headache—Methotrexate—systemic scleroderma	0.000287	0.000323	CcSEcCtD
Atomoxetine—Nausea—Methotrexate—systemic scleroderma	0.000272	0.000306	CcSEcCtD
